ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
본 보고서에서는 역류성 식도염(위식도역류질환)의 임상시험에 대해 조사 분석하여 각국의 임상시험수와 평균등록수의 데이터와 임상시험 중의 유명한 약제의 정보 등을 제공합니다.
목차
목차
표 목록
도표 목록
보고서 안내
GlobalData의 임상시험 보고서의 범위
임상시험 : 지역별
임상시험과 평균등록수 : 국가별
아시아태평양의 임상시험에 기여하고 있는 주요 5개국
유럽의 임상시험에 기여하고 있는 주요 5개국
북미의 임상시험에 기여하고 있는 상위 국가
중동 및 아프리카의 임상시험에 기여하고 있는 주요 5개국
중남미의 임상시험에 기여하고 있는 주요 5개국
G7 국가의 임상시험 : 소화기 임상시험에서 차지하는 역류성 식도염(위식도역류질환)의 비율
G7 국가의 임상시험 : 위상별
G7 국가의 임상시험 : 시험 상태별
E7 국가의 임상시험 : 소화기 임상시험에서 차지하는 역류성 식도염(위식도역류질환)의 비율
E7 국가의 임상시험 : 페이즈별
E7 국가의 임상시험 : 시험 상태별
임상시험 : 페이즈별
진행중의 시험 : 페이즈별
임상시험 : 시험 상황별
임상시험: 엔드포인트 상태별
일정 기간에 걸쳐 채용된 피험자
임상시험 : 스폰서 유형별
저명한 스폰서
역류성 식도염(위식도역류질환) 치료의 임상시험에 참가하고 있는 주요 기업
저명한 약물
역류성 식도염(위식도역류질환)에 관한 최신의 임상시험 뉴스
2025년 9월 23일 : Cinclus Pharma, European Gastroenterology Week(UEGW)에서 Linaprazan Glurate의 데이터를 발표
2025년 9월 12일 : Cinclus, 미란성 위식도 역류증(GERD)의 치료제로서 Linaprazan Glurate를 평가하는 HEEALING 1단계 3시험에서 첫 환자의 스크리닝을 발표
2025년 8월 29일 : Cinclus Pharma, 미란성 위식도 역류증(GERD) 환자를 대상으로 한 Linaprazan Glurate의 HEEALING 1단계 3 시험을 개시
2025년 8월 18일 : Onconic Therapeutics의 P-CAB 약 Jacqbo가 중국에서 3단계 임상시험을 무사히 완료하여 제품 승인 신청 중
2025년 8월 15일 : Livzon, JP-1366정의 등록 및 판매 승인 신청의 수리에 관한 자주적 발표
2025년 8월 7일 : 세벨라, GERD 치료제 테고프라잔의 3단계 TRIUMpH 프로그램이 24주간의 유지요법 단계에서 양호한 결과를 보이고 무사히 완료되었다고 발표
2025년 7월 30일 : Anaprazole Sodium의 역류성 식도염에 대한 적응의 3단계 임상시험의 환자 등록 완료에 관한 자발적 발표
임상시험 프로파일의 스냅샷
부록
SHW
영문 목차
영문목차
GlobalData's clinical trial report, "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Global Clinical Trials Review, 2025" provides an overview of Reflux Esophagitis (Gastroesophageal Reflux Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Reflux Esophagitis (Gastroesophageal Reflux Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents
List of Tables
List of Figures
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Reflux Esophagitis (Gastroesophageal Reflux Disease) to Gastrointestinal Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Reflux Esophagitis (Gastroesophageal Reflux Disease) to Gastrointestinal Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Reflux Esophagitis (Gastroesophageal Reflux Disease)
Sep 23, 2025: Cinclus Pharma to Present Linaprazan Glurate Data at the European Gastroenterology Week (UEGW)
Sep 12, 2025: Cinclus Announces Screening of First Patient in HEEALING 1 Phase III Trial Evaluating Linaprazan Glurate for the Treatment of Erosive GERD
Aug 29, 2025: Cinclus Pharma to initiate HEEALING 1 Phase III study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD)
Aug 18, 2025: Onconic Therapeutics' P-CAB drug, Jacqbo, Has Successfully Completed Phase 3 Clinical Trials in China, and Has Applied for Product Approval
Aug 15, 2025: Livzon : Voluntary Announcement Acceptance of Application for Registration and Marketing Authorization of JP-1366 Tablet
Aug 07, 2025: Sebela Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results
Jul 30, 2025: Voluntary Announcement Completion of Patient Enrollment in Phase III Clinical Trial for Indication of Drug Anaprazole Sodium in Reflux Esophagitis
